nach oben

Pathology & Oncology Research

Erschienen in:

01.04.2013 | Research

Significance of AgNORs and Ki-67 Proliferative Markers in Differential Diagnosis of Thyroid Lesions

verfasst von: Hayam A. Aiad, Manar A. Bashandy, Asmaa G. Abdou, Ahmad A. Zahran

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

We aimed to assess the utility of quantitative analysis of AgNORs and Ki67 labeling index (LI) in the differential diagnosis of different thyroid lesions. This study included: 25 papillary carcinomas, 7 follicular carcinomas, 21 follicular adenomas and 27 nodular goiters. Using a semiautomatic image analysis system, Ag NORs parameters were measured and calculated including: total area of AgNORs, mean Ag NOR number in nuclei, nuclear area, mean area of AgNOR dots per each nucleus, number of central and marginal AgNOR dots, and the relative ratio of total area of AgNOR dots/total area of nucleus. Ki67 immunostaining was performed and the LI was determined. There was a significant difference between groups of thyroid lesions regarding total area of AgNORs, Ag NOR number and number of marginal Ag NOR dots. According to receiver operating characteristic curve, Ag NORs number =2.91 and marginal Ag NORs = 2.67 were useful cut off values above which follicular carcinoma can be diagnosed with 100 % sensitivity, 79 % specificity, 76 % PPV, 100 % NPV and 85 % diagnostic accuracy for both parameters. Mean Ki67 LI in our study was 14.12 ± 2.29, 61.42 ± 3.77, 34.90 ± 3.49 and 18.60 ± 1.96 for papillary carcinoma, follicular carcinoma, follicular adenoma and nodular goiter respectively. Ki67 LI showed statistically significant difference between follicular carcinoma and follicular adenoma (p = 0.026) and between papillary carcinoma and follicular adenoma (p = 0.007). Quantification of Ag NORs and Ki67 LI could be used as helpful ancillary methods in the differentiation between different thyroid lesions.

Baloch ZW, LiVolsi VA (2002) Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 117(1):143–150CrossRefPubMed

Rosai J (2004) Thyroid gland. In: Rosai J (ed) Rosai and Ackerman’s surgical pathology, volume (2), Ch (9), 9th edn. Mosby, Edinburgh, pp 515–594

Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y, Nakao A (2003) HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50(2):173–177CrossRefPubMed

Rezk S, Brynes RK, Nelson V, Thein M, Patwardhan N, Fischer A, Khan A (2004) beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas. Endocr Pathol 15(4):329–337CrossRefPubMed

Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF (2008) Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst 20(1):36–46PubMed

Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA (2010) Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Hum Pathol 41(2):172–180CrossRefPubMed

Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31(8):1256–1264CrossRefPubMed

Sofiadis A, Tani E, Foukakis T, Kjellman P, Skoog L, Höög A, Wallin G, Zedenius J, Larsson C (2009) Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy. Int J Oncol 35(2):369–374PubMed

Slowińska-Klencka D, Klencki M, Popowicz B, Sporny S, Lewiński A (2004) Multiparameter analysis of AgNOR in thyroid lesions: comparison with PCNA expression. Histol Histopathol 19(3):785–792PubMed

10.

Mehrotra A, Goel MM, Singh K (2002) Ki-67 and AgNOR proliferative markers as diagnostic adjuncts to fine needle aspiration cytology of thyroid follicular lesions. Anal Quant Cytol Histol 24(4):205–211PubMed

11.

Howell WM (1982) Selective staining of nucleolus organiser regions (NORs). In: Busch H, Rothblum L (eds) The cell nucleus. Vol IX. Academic, New York, pp 89–143

12.

Ploton D, Menager M, Jeannesson P, Himber G, Pigeon F, Adnet JJ (1986) Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J 18(1):5–14CrossRefPubMed

13.

Bukhari MH, Niazi S, Khan SA, Hashmi I, Perveen S, Qureshi SS, Chaudhry NA, Qureshi GR, Hasan M (2007) Modified method of AgNOR staining for tissue and interpretation in histopathology. Int J Exp Pathol 88(1):47–53CrossRefPubMed

14.

Canet V, Montmasson MP, Usson Y, Giroud F, Brugal G (2001) Correlation between silver-stained nucleolar organizer region area and cell cycle time. Cytometry 43(2):110–116CrossRefPubMed

15.

Kanematsu E, Matsui H, Deguchi T, Yamamoto O, Korematsu M, Kobayashi A, Nezasa S, Yamamoto N, Takeuchi T, Tanaka T, Kawada Y (1997) Signifcance of AgNOR counts for distinguishing carcinoma from adenoma and hyperplasia in parathyroid gland. Hum Pathol 28(4):421–427CrossRefPubMed

16.

Augustynowicz A, Dziecioł J, Barwijuk-Machała M, Dadan J, Puchalski Z, Sulkowski S (2004) Assessment of proliferative activity of thyroid Hürthle cell tumors using PCNA, Ki-67 and AgNOR methods. Folia Histochem Cytobiol 42(3):165–168PubMed

17.

Kummoona R, Jabbar A, Kareem Al-Rahal D (2008) Proliferative activity in oral carcinomas studied with Ag-NOR and electron microscopy. Ultrastruct Pathol 32(4):139–146CrossRefPubMed

18.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed

19.

Kjellman P, Zedenius J, Lundell G, Backdahl M, Farnebo LO, Hamberger B, Larsson C, Wallin G (2006) Predictors of outcome in patients with papillary thyroid carcinoma. Eur J Surg Oncol 32(3):345–352CrossRefPubMed

20.

Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A (2010) Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg 34(12):3015–3021CrossRefPubMed

21.

Mar KC, Eimoto T, Nagaya S, Tateyama H (2006) Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 48:801–807CrossRef

22.

Mehrotra P, Gonzalez MA, Johnson SJ, Coleman N, Wilson JA, Davies BR, Lennard TW (2006) Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope 116:1434–1438CrossRefPubMed

23.

Królicka A, Kobierzycki C, Puła B, Podhorska-Okołów M, Piotrowska A, Rzeszutko M, Rzeszutko W, Rabczyński J, Domosławski P, Wojtczak B, Dawiskiba J, Dzięgiel P (2010) Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours. Anticancer Res 30(12):4945–4949PubMed

24.

Heikkilä A, Siironen P, Hagström J, Heiskanen I, Sankila R, Louhimo J, Haglund C, Arola J (2010) Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS 118(11):846–854CrossRefPubMed

25.

Pujani M, Arora B, Pujani M, Singh SK, Tejwani N (2010) Role of Ki-67 as a proliferative marker in lesions of thyroid. Indian J Cancer 47(3):304–307CrossRefPubMed

26.

Delellis RA, Lloyd RV, Heitz PU, Eng C (eds) (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of endocrine organs. IARC Press, Lyon

27.

Aubele M, Biesterfeld S, Derenzini M, Hufnagl P, Martin H, Ofner D, Ploton D, Ruschoff J (1994) Guidelines of AgNOR quantitation. Zentralbl Pathol 140:107–108PubMed

28.

Hufnagl P, Guski H, Schulz HJ (1994) Measuring of AgNORs using image analysis. Zentralbl Pathol 140(1):31–35PubMed

29.

Słowińska-Klencka D, Klencki M, Popowicz B, Lewiński A (2003) AgNOR quantification in the diagnosis of follicular pattern thyroid lesions. Anal Quant Cytol Histol 25(6):347–352PubMed

30.

Solymosi T, Toth V, Sapi Z, Bodo M, Gal I, Csanate L (1996) Diagnostic value of AgNORs method in thyroid cytopathology: correlation with morphometric measurements. Diagn Cytopathol 14:140–144CrossRefPubMed

31.

Asorta S, Sharma J (2008) Role of AgNors in thyroid lesions on fine needle aspiration cytology smears. J Cytol 25:18–22CrossRef

32.

Cornianu M, Milos L, Golu L, Taban S, Milos A (2006) Proliferative activity of thyroid hurthle cell tumors. Acta Endocrinologica (Buc) 3:269–282CrossRef

33.

Lewy-Trenda I, Janezukowics J, Wierzchniewska L (2006) Practical application of proliferation markers (MIB-I, PCNA, AgNOR) expression analysis of differential diagnostics of nodular thyroid lesions. Wiad Lek 59(1-2):32–37, abstractPubMed

34.

Ciobanu D, Căruntu ID, Vulpoi C, Florea N, Giuşcă SE (2006) Morphometric parameters and silver stain used in diagnosis of thyroid follicular diseases. Rom J Morphol Embryol 47(4):323–330PubMed

35.

Rüschoff J, Prasser C, Cortez T, Höhne HM, Hohenberger W, Hofstädter F (1993) Diagnostic value of AgNOR staining in follicular cell neoplasms of the thyroid: comparison of evaluation methods and nucleolar features. Am J Surg Pathol 17(12):1281–1288CrossRefPubMed

36.

Hepburn PJ, Glynne-Jones E, Goddard L, Gee JM, Harper ME (1995) Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochem J 27(3):196–203PubMed

37.

Ronckers C, Ron E (2006) Thyroid cancer. In, Freedman LS, Edwards BK, Ries LAG, Young JL (eds). Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. National Cancer Institute. NIH Pub. No. 06-5873. Bethesda, MD, pp 121–130

38.

Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV (1998) Expression of p27/kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11(2):169–174PubMed

39.

Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd R (2000) Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 13(2):186–192CrossRefPubMed

40.

Horii A, Yoshida J, Sakai M, Okamoto S, Honjo Y, Mitani K, Hattori K, Kubo T (1999) Ki-67 positive fractions in benign and malignant thyroid tumours: application of flow cytometry. Acta Otolaryngol 119(5):617–620CrossRefPubMed

41.

Rickert D, Mittermayer C, Lindenfelser R, Biesterfeld S (2000) MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland. Anal Quant Cytol Histol 22(3):229–234PubMed

42.

Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz VS, Lloyd RV (2000) p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol 13(9):1014–1019CrossRefPubMed

43.

Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A (2003) Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment and survival. Cancer 97(5):1181–1185CrossRefPubMed

Titel: Significance of AgNORs and Ki-67 Proliferative Markers in Differential Diagnosis of Thyroid Lesions
verfasst von: Hayam A. Aiad
Manar A. Bashandy
Asmaa G. Abdou
Ahmad A. Zahran
Publikationsdatum: 01.04.2013
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 2/2013
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-012-9565-1

Springer Medizin

Significance of AgNORs and Ki-67 Proliferative Markers in Differential Diagnosis of Thyroid Lesions

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

The Expression of Non-Mast Histamine in Tumor Associated Microvessels in Human Colorectal Cancers

Melanoma Screening in a Hungarian Nuclear Power Plant

Radioguided Occult Lesion Localisation Versus Wire-Guided Lumpectomy in the Treatment of Non-Palpable Breast Lesions

Selected Immuno-Histochemical Markers in Curettage Specimens and their Correlation with Final Pathologic Findings in Endometrial Cancer Patients

Genetic Variations in XRCC1 Gene in Sporadic Head and Neck Cancer (HNC) Patients

Ribosomal Protein S6 Phosphorylation is Associated with Epithelial Dysplasia and Squamous Cell Carcinoma of the Oral Cavity

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie